Development of HDAC inhibitors

Japanese Journal of Cancer and Chemotherapy

Volumn 37, Issue 9, 2010, Pages 1665-1668

  Sowa, Yoshihiro ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Cutaneous T cell lymphoma; HDAC inhibitor; Romidepsin; Vorinostat

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; ROMIDEPSIN; VORINOSTAT;

ARTICLE; CUTANEOUS T CELL LYMPHOMA; DRUG APPROVAL; DRUG MECHANISM; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; MONOTHERAPY; TREATMENT OUTCOME; UNITED STATES;

EID: 79960787196     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Friend C, Scher W, Holland JG, et al: Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide. Proc Natl Acad Sci USA 68: 378-382, 1971.
2. Richon VM, Webb Y, Merger R, et al: Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sei USA 93: 5705-5708, 1996.
3. Yoshida M, Nomura S and Beppu T: Effects of trichostatins on differentiation of murine erythroleukemia cells. Cancer Res 47: 3688-3691, 1987.
4. Yoshida M, Kijima M, Akita M, et al: Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265: 17174-17178, 1990.
5. Nakajima H, Kim YB, Terano H, et al: FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 241: 126-133, 1998.
6. Richon VM, Emiliani S, Verdin E, et al: A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 95: 3003-3007, 1998.
7. Duvic M, Talpur R, Ni X, et al: Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109: 31-39, 2007.
8. Olsen EA, Kim YH, Kuzel TM, et al: Phase II b multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25: 3109-3115, 2007.
9. Fujiwara Y, Yamamoto N, Yamada Y, et al: Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors. Cancer Sci 100: 1728-1734, 2009.
10. Watanabe T, Kato H, Kobayashi Y, et al: Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. Cancer Sci 101: 196-200, 2010.
11. Piekarz RL, Frye R, Turner M, et al: Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 27: 5410-5417, 2009.
12. Giles F, Fischer T, Cortes J, et al: A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 12: 4628-4635, 2006. (Pubitemid 44297814)
13. Ellis L, Pan Y, Smyth GK, et al: Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 14: 4500-4510, 2008.
14. Rathkopf D, Wong BY, Ross RW, et al: A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol 66: 181-189, 2010.
15. Wilson AJ, Chueh AC, Tögel L, et al: Apoptotic sensitivity of colon cancer cells to histone deacetylase inhibitors is mediated by an Sp1/Sp3-activated transcriptional program involving immediate-early gene induction. Cancer Res 70: 609-620, 2010.